Combination of PD-1 blockade and RetroNectin®-activated cytokine-induced killer in preheavily treated non-small-cell lung cancer: a retrospective study.
Combination of PD-1 blockade and RetroNectin®-activated cytokine-induced killer in preheavily treated non-small-cell lung cancer: a retrospective study.
复制标题
DOI：
10.2217/imt-2018-0125
复制
发表时间：
2018-10
期刊：
影响因子：
2.8
通讯作者：
Lingdi Zhao;Lu Han;Yong Zhang;Tiepeng Li;Yonghao Yang;Wei Li;Yiman Shang;Hongwei Lin;Q. Gao-Q.-G
中科院分区：
文献类型：
--
作者：
Lingdi Zhao;Lu Han;Yong Zhang;Tiepeng Li;Yonghao Yang;Wei Li;Yiman Shang;Hongwei Lin;Q. Gao-Q.-G
目的分析PD-1阻断联合RetroNectin®激活的细胞因子诱导杀伤细胞(R-CIK)治疗晚期非小细胞肺癌(NSCLC)的疗效。方法对接受PD-1阻断联合R-CIK细胞治疗且至少两种方案治疗失败的晚期非小细胞肺癌患者进行回顾性分析。结果既往治疗方案的中位数为3个(2~7个)。2名患者部分缓解，4名患者病情稳定，1名患者病情恶化。中位进展时间为4.8个月。结论PD-1阻断联合R-CIK细胞治疗至少两种治疗方案失败的晚期非小细胞肺癌是安全有效的。
AIM To analyze the efficacy of PD-1 blockade combined with RetroNectin®-activated cytokine-induced killer (R-CIK) cells in preheavily treated advanced non-small-cell lung cancer (NSCLC). METHODS We retrospectively analyzed patients with advanced NSCLC who received PD-1 blockade combined with R-CIK cells whose treatments failed at least two regimens. RESULTS The median number of previous treatment regimens was three (range: 2-7). Partial remission was achieved in two patients, stable disease in four patients and one patient experienced progressive disease. The median time-to-progression was 4.8 months. CONCLUSION PD-1 blockade combined with R-CIK cells is safe and effective in patients with advanced NSCLC who have failed at least two treatment regimens.